Division of Thoracic Surgery, Princess Margaret Cancer Center, University Health Network, University of Toronto, Toronto, Ontario, Canada.
Division of Urology, Princess Margaret Cancer Center, University Health Network, University of Toronto, Toronto, Ontario, Canada.
J Thorac Cardiovasc Surg. 2021 Mar;161(3):856-868.e1. doi: 10.1016/j.jtcvs.2020.10.158. Epub 2020 Nov 30.
Men with metastatic nonseminomatous germ cell tumors (NSGCTs) often present with residual chest tumors after chemotherapy. We examined the pathologic concordance of intrathoracic disease and outcomes based on the worst pathology of disease resected at first thoracic surgery.
A retrospective analysis was performed of consecutive patients undergoing thoracic resection for metastatic NSGCT in our institution between 2005 and 2018.
Eighty-nine patients (all men) were included. The median age was 29 years (interquartile range [IQR], 23-35 years). Primary sites were testis (n = 84; 94.4%) and retroperitoneum (n = 5; 5.6%). Eighty-seven patients received chemotherapy before undergoing surgery. Nineteen patients (21.3%; group 1) had malignancy resected at first surgery (OR1), and the other 70 patients had benign disease at OR1 (78.7%; group 2). Concordant pathology between lungs was 85.2% in group 1 and 91% in group 2, and between lung and mediastinum was 50% in group 1 and 72.7% in group 2. Despite no teratoma at OR1, 3 patients (15.8%) in group 2 had resection of teratoma (n = 2) or malignancy (n = 1) at future surgery. After a mean follow-up of 65.5 months (IQR, 23.1-89.2 months) for group 1 and 47.7 months (IQR, 13.0-75.1 months) for group 2, overall survival was significantly worse for group 1 (68.4% vs 92.9%; P = .03).
The wide range of pathology resected in patients with intrathoracic NSGCT metastases requires careful decision making regarding treatment. Pathologic concordance between lungs is better than that between lung and mediastinum in patients with intrathoracic NSGCT metastases. Aggressive surgical management should be considered for all residual disease due to the low concordance between sites and the potential for excellent long-term survival even in patients with chemotherapy-refractory disease.
患有转移性非精原细胞瘤生殖细胞肿瘤(NSGCT)的男性在化疗后常出现残留的胸部肿瘤。我们根据首次胸部手术切除的疾病最严重的病理检查,研究了胸腔内疾病的病理一致性和结局。
对 2005 年至 2018 年在我院接受胸腔切除术治疗转移性 NSGCT 的连续患者进行回顾性分析。
共纳入 89 例(均为男性)患者。中位年龄为 29 岁(四分位距 [IQR],23-35 岁)。原发部位为睾丸(n=84;94.4%)和腹膜后(n=5;5.6%)。87 例患者在手术前行化疗。19 例患者(21.3%;组 1)在首次手术时切除恶性肿瘤,而其余 70 例患者在首次手术时为良性疾病(组 2;78.7%)。组 1 中肺部和纵隔之间的病理一致性为 85.2%,组 2 中为 91%。尽管首次手术时未发现畸胎瘤,但组 2 中有 3 例(15.8%)患者在以后的手术中切除了畸胎瘤(n=2)或恶性肿瘤(n=1)。在对组 1 进行了平均 65.5 个月(IQR,23.1-89.2 个月)和对组 2 进行了 47.7 个月(IQR,13.0-75.1 个月)的随访后,组 1 的总生存率明显差于组 2(68.4%比 92.9%;P=0.03)。
患有胸腔内 NSGCT 转移的患者切除的病变范围广泛,需要仔细决定治疗方法。胸腔内 NSGCT 转移患者的肺部病理一致性优于肺部和纵隔之间的病理一致性。由于部位之间的一致性较低,且即使在化疗耐药的患者中也能获得极好的长期生存率,因此应考虑对所有残留疾病进行积极的手术治疗。